NCT05760378View on ClinicalTrials.gov

Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.

PHASE3RecruitingINTERVENTIONAL
Enrollment

223

Participants

Timeline

Start Date

March 17, 2023

Primary Completion Date

January 1, 2025

Study Completion Date

January 1, 2027

Conditions
Triple-Negative Breast Cancer
Interventions
DRUG

Famitinib

TKI

DRUG

Camrelizumab

PD1 inhibitor

DRUG

nab-Palitaxel/Capecitabine/Eribulin Mesylate/Carboplatin

TPC

Trial Locations (1)

200032

RECRUITING

Breast cancer institute of Fudan University Cancer Hospital, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER